Evidence from multiple model systems supports a shift away from heme transport and toward metabolic dysfunction and oxidative stress as key drivers of TANGO2 deficiency.

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...